Crinetics Pharmaceuticals Stock Today
| CRNX Stock | USD 57.70 1.63 2.91% |
Performance3 of 100
| Odds Of DistressLess than 6
|
Crinetics Pharmaceuticals is trading at 57.70 as of the 21st of November 2024; that is 2.91 percent increase since the beginning of the trading day. The stock's open price was 56.07. Crinetics Pharmaceuticals has only a 6 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Note, on October 3, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Crinetics Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2018 | Category Healthcare | Classification Health Care |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. The company has 92.74 M outstanding shares of which 6.94 M shares are currently shorted by private and institutional investors with about 8.47 trading days to cover. More on Crinetics Pharmaceuticals
Moving together with Crinetics Stock
Moving against Crinetics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Crinetics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, Co-Founder, Director | Scott Struthers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCrinetics Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Crinetics Pharmaceuticals' financial leverage. It provides some insight into what part of Crinetics Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Crinetics Pharmaceuticals (CRNX) is traded on NASDAQ Exchange in USA. It is located in 6055 Lusk Boulevard, San Diego, CA, United States, 92121 and employs 290 people. Crinetics Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.2 B. Crinetics Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 92.74 M outstanding shares of which 6.94 M shares are currently shorted by private and institutional investors with about 8.47 trading days to cover.
Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (166.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6.
Check Crinetics Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCrinetics Pharmaceuticals holds a total of 92.74 Million outstanding shares. The majority of Crinetics Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Crinetics Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Crinetics Pharmaceuticals. Please pay attention to any change in the institutional holdings of Crinetics Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On October 3, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Crinetics Pharmaceuticals's common stock.
Check Crinetics Ownership Details
Crinetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hhg Plc | 2024-06-30 | 2.5 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.7 M | |
| Cormorant Asset Management, Llc | 2024-06-30 | 1.4 M | |
| Orbimed Advisors, Llc | 2024-06-30 | 1.3 M | |
| First Light Asset Management, Llc | 2024-06-30 | 1.2 M | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.1 M | |
| Artal Group S A | 2024-06-30 | 1.1 M | |
| Novo A/s | 2024-09-30 | 1000 K | |
| Vanguard Group Inc | 2024-09-30 | 6.3 M | |
| Blackrock Inc | 2024-06-30 | 6.2 M |
Crinetics Pharmaceuticals Historical Income Statement
Crinetics Stock Against Markets
Crinetics Pharmaceuticals Corporate Management
| Jeff Knight | Chief Officer | Profile | |
| James Hassard | Chief Officer | Profile | |
| Adriana MBA | Chief Officer | Profile | |
| Gayathri Diwakar | Head Relations | Profile | |
| Dana MD | Chief Officer | Profile | |
| Marc Wilson | Chief Officer | Profile |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.